Given that several anti-PI3K medications are unable to completely suppress tumour growth in PTEN-deficient malignancies, available data suggest that PTEN has tumour-suppressive effects that extend beyond PI3K pathway inhibition (15, 16). This evidence concerns the gene PTEN and neoplasm.